Mouth Cancer
7
1
1
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
DESTINY-PANTUMOUR04
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
Real-time Molecular Diagnosis of Oral Precancer
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Wild Type p53 Adenovirus for Oral Premalignancies
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors